Lower versus standard radiation in stage II nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial compares a lower dose of radiation (40.2 Gy) to the standard dose (49.2 Gy) for patients with stage II nasopharyngeal carcinoma that has shrunk after initial chemoimmunotherapy. The goal is to see if the lower dose works just as well while potentially causing fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of nasopharyngeal cancer called non-keratinizing carcinoma (WHO type II or III).
- Your cancer is stage II (T1-3N2M0 or T3N0-1M0) according to the AJCC/UICC 9th edition staging system.
- You have a good performance status (KPS score of 70 or higher).
- Your blood counts (white cells, platelets, hemoglobin) are within normal limits.
- After three cycles of chemoimmunotherapy, your tumor has completely or partially disappeared on scans.
- After induction chemotherapy, the level of EBV DNA in your blood is undetectable or zero.
- Your liver and kidney function tests are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
This Phase 2 study tests whether using a special scan (PET/CT) to guide radiation can safely reduce the radiation dose for people with nasopharyngeal cancer. It may help lessen side effects while still treating the cancer effectively.
This Phase 3 study tests whether giving a reduced amount of radiotherapy can work as well as the standard dose for certain people with stage II–III nasopharyngeal cancer who respond well after initial chemotherapy. It’s designed for patients whose cancer markers improve after 3 chemotherapy cycles, to potentially reduce treatment side effects while keeping cancer control.
This trial studies whether lowering the radiation dose to a smaller area around the tumor is safe and effective for people with newly diagnosed nasopharyngeal cancer that has not spread. It may reduce side effects while still curing the cancer.
This trial compares two approaches for people with early-stage nasopharyngeal cancer that can be removed with surgery. It tests whether giving less intense chemotherapy and radiation after surgery works as well as a standard dose, with fewer side effects.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.